Setup. MiMedx Group reported Q1 2026 on April 29 — the first quarter under the CMS reset that cut skin substitute reimbursement from ASP+6% to a flat $127.14/sq cm. Headline numbers were ugly: total revenue -33.1%, Wound -59.7% YoY, GAAP operating loss -$16M. The stock is -47% over twelve months and trades like a wound care company in collapse. The cohort cross-check changes the read.

What the filing says. Wound revenue fell to $22.6M from $56M. Gross margin compressed 1,060 bps to 70.6%. Q1 annualizes to $236M against the FY2026 guide of $340-360M; the math requires Wound to recover roughly 170% from Q1 pace through Q2-Q4. CEO Bill Capper called recovery "sluggish." A 15% RIF announced April 16 targets $40M annualized savings. PSU expense reversed -$1.7M, signaling the comp committee marked performance targets as unlikely (though comp committees across the cohort are likely doing the same).

The Surgical segment grew 13.2% to $36.4M and is now 62% of total revenue. Surgical is DRG-reimbursed in hospitals — structurally insulated from the skin substitute rule. The Kennesaw manufacturing lease was extended 11 years through 2038. Two new 510(k) launches and the RegenKit PRP acquisition ($5M, Jan 2026) expanded the franchise. A $100M buyback authorized in February remains undeployed. Cash $159.8M vs $17.6M debt — net cash $142M, no covenant pressure.

What the market thinks. EV ≈$413M after net cash, against the FY26 guide midpoint $350M = 1.18x EV/sales. Peers: ORGO 0.43x, TELA 0.66x, IART 1.55x, SMTI 1.7x. MDXG sits in the depressed-wound-care band, not the surgical-medtech band. The implicit market view: Surgical doesn't sustain, the whole company is continuing decline, FY guide misses. RSI 57, RVOL 0.5x, no Form 4 P-code purchases — volume light.

Why the gap exists. Three cohort findings change the interpretation. Convatec InnovaMatrix FY26 guide is -71% (cohort-worst, took a $72M impairment); ORGO Q1 2026 guide is -50% (not yet filed); MDXG -60% sits mid-pack. Apparent peer disconfirmations are different reimbursement classes: IART Tissue Recon +6.7% is bovine dermis DRG plus FDA Warning Letter supply recovery; SNWV +3-4% is CPT 97610 ultrasound. Capper noted unnamed peers had "90-95% Medicare reductions." Within the directly affected pure-play cohort, MDXG outperformed on margin compression, balance sheet, and restructuring decisiveness.

The mispricing: Surgical at peer-median 3x EV/sales (between SMTI 1.7x and IART 1.55x at the bottom and growth-medtech 5-6x at the top) supports $435-870M Surgical EV across the multiple range. Plus net cash and a recovering Wound segment, sum-of-parts at 3x base / 4x mid / 5.5x bull is roughly $4.65 / $5.61 / $7.20 per share. Only six analysts cover MDXG. TELA hired Capper as Chairman April 29 — competitor validation; TELA already distributes MDXG's HELIOGEN.

Risks (ranked). (1) Surgical Q2 ≤+5% YoY breaks the diversification anchor. (2) AXIOFILL FDA litigation — court briefs filed January 2026; reclassification as drug/biologic causes Surgical disruption. (3) Buyback canceled or withdrawn signals covenant or acquisition stress. (4) Cohort recovers but MDXG lags — relative outperformance claim collapses. (5) Capper departs MDXG for full-time TELA role.

Catalysts. ORGO Q1 2026 10-Q (~mid-May 2026) is the first cohort disambiguator. The Q2 print in August 2026 simultaneously resolves guide trajectory, Surgical sustainability, and Wound sequential rebound. Buyback deployment is rolling — any quarterly disclosure showing repurchases is an LR 2-3 catalyst, aggressive deployment is the bottom signal. A Capper Form 4 P-code purchase would be unprecedented and material.

What would change our mind. Surgical Q2 ≤+5% YoY (kills the re-rating leg). Buyback canceled or withdrawn. ORGO Q1 actual in-line or better than -50% guide (cohort outperformance claim weakens). Stock breaks $2.50 — bear-case sum-of-parts compressed another 25%, thesis invalidation.

Probability-weighted EV. Bear 25% / -25%, Base 50% / +50%, Bull 20% / +110%, Lottery 5% / +200% (TELA combination, speculative — no direct evidence beyond the Capper Chairman role) → ~+51% over 12-18 months. Multiple-sensitivity caveat: the Surgical multiple is the swing variable. At peer-median 3x, base case compresses to +25-30%; at 4x, +50%; at 5x, +80%. Edge vs market-implied bull probability is 9-15pp after overconfidence haircut.

Evidence